Global Artificial Womb Facility Market

Global Bleeding Disorders Treatment Market

Bleeding disorders are a group of conditions in which there is a problem with the blood clotting process of the body. These disorders can lead to heavy and prolonged bleeding after an injury. Bleeding can also begin on its own. Some bleeding disorders are present at birth and are passed down through families (inherited). Others develop from illnesses, such as vitamin K deficiency, severe liver disease, and treatments, such as the use of drugs to stop blood clots (anticoagulants) or the long-term use of antibiotics.

Market Size & Growth Rate:

The bleeding disorders treatment was valued at USD 12.8 billion in 2021 and is projected to reach USD 18.6 billion by 2027, with a CAGR of 7.6% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.

Market Dynamics:

• The factors driving the growth of the bleeding disorder treatment market are the rise in the prevalence of liver disorders, anemia, and other blood coagulation disorders. The increasing awareness of bleeding disorders treatment and improving healthcare infrastructure in developing countries will also fuel the scope of market growth.

• According to WFH (World Federation of Hemophilia) data-2021, the estimated prevalence at birth and the current live birth population globally from UNICEF (at least 130 million babies are born each year), approximately 20,000 new cases of hemophilia is reported worldwide each year, of which 7,000 are severe.

• In addition, the estimated and present world male population of 7.8 billion, the anticipated number of patients with hemophilia worldwide is 815,100, about 276,900 of them are seriously ill.

• Von Willebrand disease, the most common inherited bleeding disorder in the United States caused by clotting proteins, affects a large number of people. This disease affects both men and women and affects nearly 1% of the population in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately 400 newborns in the United States are affected by haemophilia each year.

Get more details on this report - Request Free Sample

Global Bleeding Disorders in 2020

According to WFH-2021, the number of patients with hemophilia-A is projected to major growth rate, followed by Von Willebrand disease across the globe, as hemophilia-A is the first line of impact for bleeding disorders treatment platforms.

Market Drivers:

• Growing prevalence of hemophilia across the globe

• The increasing prevalence of hemophilia contributing to the rising demand for treatment options is one of the prime factors driving the hemophilia treatment market expansion.

• Severe patients need a regular hemophilia treatment regimen to maintain enough clotting factors in the bloodstream to prevent bleeding. As per the Centers for Disease Control and Prevention, hemophilia A affects 1 in 5,000 male births each year in the U.S. This considerable prevalence is set to dramatically impact the market since the number of dependent patients requiring quality care is increasing.

• Moreover, patients that receive proper care are expected to develop fewer illness conditions and experience a lower risk of severe bleeding. Thus, the continuously increasing patient number has significantly boosted the demand for hemophilia treatment that in turn will increase the product adoption rate

• The increase in research and development activities and growing awareness

• Increasing the demand for recombinant coagulation factor concentrate

Challenges:

• The side effects of the medication are anticipated to hamper the market growth

• The adverse effects of bleeding disorder therapeutics are anticipated to restrict the market growth during the forecast period. For instance, the use of coagulation factor concentrates in the treatment of hemophilia may lead to the development of alloantibodies that work against factor VIII or factor IX.

• The development of such alloantibodies occurs in around 15% to 35% of patients suffering from hemophilia A. Even though around 50% of the factor VIII or factor IX inhibitors are low tier, the high tier inhibitors can lead to increased severity of hemophilia, resulting in a greater risk of excessive bleeding to the patient.

• Moreover, treatment using plasma-derived products can increase the risks of transmitting blood-borne pathogens such as prions and HIV, if the screening process is not conducted appropriately.

• Shortage of clinicians & unfavorable reimbursement situations hampering the market growth

• The high cost associated with the hemophilia treatment

Competitive Landscape:

CSL Behring (U.S.), Grifols International (U.S.), Octapharma (Switzerland), Pfizer (U.S.), Biogen Idec, Xenetic Biosciences (U.S.), Sanofi (France), Cangene Corporation (Canada), Alnylam Pharmaceuticals (U.S.)Amgen U.S), Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.),  Prestige Consumer Healthcare Inc. (U.S.), Thea Laboratories (France),  Wellona Pharma (India),   Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan)

Key Developments:

Competitors in the global bleeding disorders market are engaged in regulatory approvals, the development of new services, and acquisition & collaborative agreements with other companies. A few expansion strategies are adopted by players operating in the bleeding disorders market.

• In February 2020, Novo Nordisk launched Esperoct, an anti-hemophilic factor in the U.S. for the treatment of adults & children with hemophilia A and to control bleeding issues even during surgery.

• In March 2019, Biotest AG received regulatory approval from 13 European countries for its product offering for the treatment of Hemophilia-A.

• In December 2019, Johnson and Johnson collaboration with Spanish multinational, Grifols, introduce a Vistaseal biological sealant, which is a blood-stopping protein spray that controls bleeding during complicated surgeries where suturing, and ligature cannot be applied.

• In December 2019, Bayer AG has collaborated for three-year with the children’s hospital. The main motto of collaboration is “The development of small molecules to treat hemophilia A and B”.

• In 2018, on the occasion of the 70th anniversary of the National Hemophilia Foundation (NHF), a Red Tie Campaign was launched to create awareness about bleeding disorders and increase the accessibility of quality healthcare to patients suffering from bleeding disorders by providing them with health insurance, and lifetime benefits.

• In 2018, European Association for Hemophilia and Allied Disorders formed a working group on women and bleeding disorders after receiving approval for the proposal. The working group focuses on educating healthcare providers and understanding the needs of women with bleeding disorders.

Artificial Womb Facility Market

Artificial Womb Facility Market is segmented By Facility (Bioreactors, Extrauterine Support Devices, Other), By Technology (Neonatal Intensive Care Units (NICUS), Birthing Centres, Others), By Application (Prenatal Care, Neonatal Care), By End-User (Hospitals, Newborn Care Centres, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2023-2030.

The Artificial Womb Facility Market was valued at US$ 285.54 million in 2022 and the total market is forecasted to grow at a CAGR of 8.95% from 2023 to 2030, reaching nearly US$ 520.65 million by 2030.

Overview and Scope

The worldwide artificial womb facility market includes equipment and systems that imitate the environment of a mother's womb for the gestation of a baby outside the mother's body. Extrauterine support systems, or artificial wombs, are another name for these devices and systems. The sector is rapidly expanding with many types of devices and systems, such as closed systems, open systems, and hybrid systems.

The industry is being pushed by the rising occurrence of preterm deliveries, which can lead to long-term health issues for the baby. Artificial womb facilities have the potential to enhance preterm newborn outcomes by providing a more regulated and supportive environment for development. Advances in technology and medical research are propelling the industry, resulting in the creation of sophisticated and effective extrauterine support systems. In addition, greater investment and support from governments, private companies, and research organisations are projected to boost the industry.

With well-established healthcare infrastructure and significant levels of investment in medical research and technology, major nations such as North America and Europe are now leading the worldwide artificial womb facility sector. However, the market in the Asia-Pacific region is predicted to increase considerably because to the rising frequency of preterm births and rising healthcare spending in developing nations.

Market Dynamics

Artificial Womb Facility Market Drivers Several factors are predicted to generate considerable growth in the worldwide artificial womb facility market throughout the forecast period. Premature births, which are a major source of infant mortality and long-term health concerns, are one of the important factors. The use of artificial wombs improves preterm baby survival rates and lowers the risk of problems. Another driving factor is the increased demand for assisted reproductive technologies (ART) and fertility treatments, which are becoming more frequent as infertility rates and childbearing delays rise. By providing a more stable and regulated environment for embryo growth, artificial wombs assist to enhance ART success rates.

To further fuel this industry, advances in medical technology and biotechnology are driving the development of more sophisticated and effective artificial womb facilities. These facilities offer a range of benefits, such as improved monitoring and control of foetal development, reduced risk of infections and other complications, and enhanced opportunities for research and development. Moreover, there is increasing recognition of the potential of artificial womb facilities to address a range of medical and ethical issues related to pregnancy and childbirth.

Restraints The high cost of developing and implementing these technologies makes it difficult for significant firms to compete. Artificial womb facilities need substantial investment in R&D, production, and regulatory compliance, which might be prohibitively expensive for many healthcare providers and consumers. Furthermore, the scarcity of experienced healthcare workers and the specialised equipment necessary to operate and maintain these facilities raises the prices and limits their general adoption.

Another impediment to the deployment of artificial womb facilities is the absence of defined regulatory frameworks and ethical requirements. The evolution of these technologies raises a number of complex ethical and legal issues, including the definition of life and personhood, the rights and responsibilities of parents and healthcare providers, and the potential risks and benefits of these technologies for infants and society as a whole. In the lack of clear and uniform norms and standards, stakeholders such as healthcare professionals, patients, and investors face confusion and hesitancy.

Artificial Womb Facility Opportunities The worldwide artificial womb facility market provides chances for firms working in this field to grow their products and gain market share. One of the most promising potential is to create more advanced and specialised artificial womb facilities that cater to specific medical demands and situations. The use of artificial wombs to help the growth of preterm newborns with certain health concerns, such as lung or heart difficulties, is becoming more popular. Companies who find creative solutions to meet these demands will have greater prospects for growth.

Extending the uses of artificial womb facilities beyond infant care and assisted reproduction technologies can provide market participants with a competitive advantage. Artificial wombs, for example, have the potential to be utilised for foetal tissue engineering, medication discovery and testing, and other research and development applications. Companies that can form successful relationships with research institutes and other stakeholders to investigate these potential stand to gain market share and revenue development.

Companies engaged in the artificial womb facility business can also increase their worldwide reach and enter new and emerging markets. This involves building operations in growing countries such as Asia, Africa, and Latin America, where superior medical technology and infrastructure are in high demand. Companies that can traverse these markets' distinct legislative and cultural settings and build successful distribution and marketing strategies are likely to achieve great long-term growth and profitability.

Artificial Womb Facility Challenges There are substantial obstacles in this business that may limit growth and acceptance in the next years, with the complexity and technical sophistication of these technologies requiring highly specialised skills and experience to create, install, and operate being one of the primary challenges. The scarcity of competent people in this industry may slow the rate of innovation and market expansion.

Another difficulty is the lack of strong data and evidence to demonstrate the safety and effectiveness of artificial womb facilities. The development of these technologies necessitates significant testing and validation, including clinical studies, to verify their efficacy and safety. This method is time-consuming and expensive, and it may also encounter ethical problems connected to the use of human beings in research. Furthermore, there may be inadequate evidence on the long-term effects and ramifications of employing artificial womb facilities, which might generate confusion and hesitancy among stakeholders.

Finally, there is the challenge of public acceptability and perception of artificial womb facilities. These technologies present a number of complicated ethical and social challenges, such as worries about the monetization of reproduction, the consequences for conventional family systems, and the possibility of misuse or abuse. Building trust and acceptability among stakeholders and the broader public will need public education and involvement.

Artificial Womb Facility Trends The rising emphasis on improving newborn outcomes and lowering infant mortality rates are two significant market trends that are expected to affect the growth and evolution of the global artificial womb market throughout the projected period. Artificial womb facilities provide a potential way to providing essential care for preterm children and those with congenital defects, allowing them to develop in an environment similar to the womb and lowering the risk of problems and long-term disability.

Another emerging trend is the increased need for personalised and precision medical techniques. Artificial womb facilities enhance child development by providing specialised and individualised care depending on their distinct demands and circumstances. This will almost certainly spur the development of improved monitoring and diagnostic systems capable of providing real-time data and insights into newborn health and development.

The application of artificial intelligence (AI) and machine learning (ML) is also a prominent development in the market for artificial womb facilities. These technologies can assist healthcare practitioners in analysing vast amounts of data and optimising newborn care techniques in artificial womb facilities. For example, based on specific patient data, AI and ML systems can forecast the risk of problems or unfavourable outcomes, allowing healthcare personnel to intervene early and avert unpleasant occurrences. In the artificial womb facility industry, there is also a movement towards collaboration and partnerships among players. Healthcare providers, academic institutions, government organisations, and private enterprises are increasingly collaborating to enhance R&D, exchange information and resources, and develop best practises and standards for the use of these technologies. This pattern likely to drive innovation and accelerate the adoption and commercialization of artificial womb facilities over the forecast period.

Maximise has conducted a complete study of the main and supporting variables that impact the worldwide market, and the entire report offers specific information on each of the market dynamics elements. The data will assist businesses in understanding market trends and scenarios, as well as whether it is profitable to invest in such a sector and its prospective future.

Segment Analysis

The worldwide artificial womb facility market is classified by technology, facility, application, end-user, and geography. Artificial womb facilities are divided into bioreactors, extrauterine support devices, and other sophisticated technologies, as well as specialised neonatal intensive care units (NICUs), birthing centres, and others, dependent on the technology utilised.

Based on application, The market is separated into two segments: prenatal care and neonatal care. The neonatal care sector is likely to lead the market due to the increasing prevalence of preterm births and the growing need for sophisticated care technologies to enhance infant outcomes. The market is divided into three segments based on end-user: hospitals, newborn care centres, and others. Hospitals are likely to be the most common end-user category because to their widespread availability and accessibility, as well as their ability to deliver a variety of services to patients. Neonatal care centres are also predicted to expand significantly due to their specialised skills and focus on providing care to preterm and unwell newborns.

Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a mature market with a significant market share due to the high frequency of preterm births and the existence of a large number of healthcare providers and research organisations. Europe is likely to increase significantly as the focus shifts to improving newborn outcomes and lowering infant death rates. The Asia Pacific area is a rapidly expanding market, with the largest population base and increasing demand for advanced care technology, particularly in China and India.

The complete study created by Maximise includes a full analysis of which segment is the most profitable to invest in and where the Artificial Womb Facility company is most likely to blossom and provide high profits, taking into account all considerations.

Regional Analysis

The worldwide artificial womb facility market is divided into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is predicted to lead the market because to the high frequency of preterm births and the existence of a significant number of healthcare providers and research institutes. The area has seen tremendous breakthroughs in newborn care technology, and the growing emphasis on improving neonatal outcomes is projected to boost demand for artificial womb facilities. Furthermore, the availability of improved healthcare infrastructure and attractive reimbursement policies are projected to drive market expansion.

Europe is likely to increase significantly as the focus shifts to improving newborn outcomes and lowering infant death rates. The region has seen tremendous breakthroughs in medical technology and has a well-established healthcare system. Furthermore, the growing use of improved technologies and the rising prevalence of premature births are likely to boost market expansion.

Because of its enormous population base and rising demand for advanced care technologies in countries such as China and India, the Asia Pacific region is likely to develop the quickest. Significant investments in healthcare infrastructure have occurred in the area, and the increased emphasis on lowering infant death rates is likely to boost market expansion. Furthermore, due to specific environmental variables, the demand for artificial womb facilities in this region is likely to rise. Maximize's full study has more information on the PESTLE variables that are predicted to drive the industry and those that will pose restrictions to its development and expansion.

Due to a lack of sophisticated healthcare facilities and the relatively low adoption of new medical technology, Latin America, the Middle East, and Africa are likely to have modest to restricted growth.

Artificial Womb Facility Market Competitive Analysis

With a large number of participants in the industry, the worldwide artificial womb facility market is extremely competitive and fragmented. The presence of multiple established businesses as well as new entries in the industry has resulted in heated rivalry among players. To achieve a competitive advantage, market participants are focused on creating novel technologies and increasing their product ranges.

Consolidations, mergers, and acquisitions have transformed the market environment significantly. Womb Institute, a start-up located in the United States, for example, bought Synthetix, a Canadian biotech business, in 2019 to develop sophisticated artificial womb technology. SomaGenics, a biotech business located in the United States, will collaborate with the University of California, San Francisco (UCSF) in 2020 to develop novel artificial womb technologies for the treatment of premature delivery.

The high level of technological competence necessary to develop and build artificial womb facilities makes it difficult for new competitors to enter the industry. Furthermore, the industry is heavily regulated, needing different permits and certifications from regulatory authorities, which raises entry hurdles for new businesses. Womb Institute, The Children's Hospital of Philadelphia, Preterm Birth Initiative, and Synthetix are among the market's prominent participants. To acquire a competitive advantage in the industry, these firms are focusing on creating new technologies and extending their product ranges.

To be able to function successfully, organisations joining this field should thoroughly examine their skills and design a market entrance and differentiation plan, according to Maximise. To maintain their competitive edge, new entrants should also focus on innovation, distinctiveness, distribution network growth, and strategic alliances.

Artificial Womb Facility Market, by Region 

• North America (United States, Canada and Mexico)

• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)

• Asia Pacific (China, South Korea, Japan, India, Australia, I